ENTITY
Elevar Therapeutics
Elevar Therapeutics
PulseAugur coverage of Elevar Therapeutics — every cluster mentioning Elevar Therapeutics across labs, papers, and developer communities, ranked by signal.
Total · 30d
2
2 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
0 over 90d
TIER MIX · 90D
TOPICS
SENTIMENT · 30D
1 day(s) with sentiment data
RECENT · PAGE 1/1 · 2 TOTAL
-
Investor boosts Pop Mart stake; FDA delays Hengrui drug; AI models GPT-5.6 and Claude mentioned
Investor Duan Yongping has increased his stake in Pop Mart, raising his shareholding to 7.65%. In other news, Hengrui Medicine received a complete response letter from the US FDA regarding its biologics license applicat…
-
Hengrui Medicine's Liver Cancer Drug Faces Third FDA Delay
Hengrui Medicine has announced that its combination therapy, known as "Shuang Ai," has received another complete response letter (CRL) from the U.S. Food and Drug Administration (FDA). This marks the third delay in appr…